

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
10 June 2021 (10.06.2021)



(10) International Publication Number
WO 2021/113662 A2

(51) International Patent Classification:
A61K 47/56 (2017.01) *A61P 27/02* (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2020/063347

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:
04 December 2020 (04.12.2020)

(25) Filing Language: English

(26) Publication Language: English

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(30) Priority Data:
62/943,724 04 December 2019 (04.12.2019) US
63/021,023 06 May 2020 (06.05.2020) US
63/108,234 30 October 2020 (30.10.2020) US

(71) Applicant: **ASHVATTHA THERAPEUTICS, INC.**
[US/US]; 1235 Radio Road, Suite 200, Redwood City, California 94065 (US).

(72) Inventors: **CLELAND, Jeffrey**; 1235 Radio Road, Suite 200, Redwood City, California 94065 (US). **SHARMA, Rishi**; 1235 Radio Road, Suite 200, Redwood City, California 94065 (US). **APPIANI, Santiago**; 1235 Radio Road, Suite 200, Redwood City, California 94065 (US).

(74) Agent: **PABST, Patrea L.** et al.; Pabst Patent Group LLP, 1545 Peachtree Street, NE, Suite 320, Atlanta, Georgia 30309 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO THE EYE

(57) Abstract: Dendrimer compositions and methods for the treatment of one or more inflammatory and/or angiogenic diseases and/or disorders of the eye include hydroxyl-terminated dendrimers complexed or conjugated with one or more active agents for the treatment or alleviation of one or more symptoms of the diseases of the eye, and/or for diagnosing the diseases and/or disorders of the eye. The dendrimers may include one or more ethylene diamine-core poly(amidoamine) (PAMAM) hydroxyl-terminated generation-4, 5, 6, 7, 8, 9, or 10 dendrimers. The active agents may be VEGFR tyrosine kinase inhibitors including sunitinib or analogues thereof. Preferably, the compositions are suitable for administration via a systemic route to target activated microglia/macrophages in retina/choroid.



WO 2021/113662 A2